<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; abbott</title>
	<atom:link href="http://www.tapanray.in/tag/abbott/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Being Eclectic – A Pharma Leadership Quality In The New Normal</title>
		<link>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=being-eclectic-a-pharma-leadership-quality-in-the-new-normal</link>
		<comments>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 21 Jun 2021 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[gamification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10531</guid>
		<description><![CDATA[It’s no-brainer that since the onset of Covid pandemic, digitalization initiative of many pharma companies in critical facets of business operations, has reached a new high. The process is now fast accelerating with the adoption of avant-garde ideas, and scalable &#8230; <a href="http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Come Covid-19 Drug And Vaccine, Pharma Will Get Back To The Traditional Mode</title>
		<link>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode</link>
		<comments>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/#comments</comments>
		<pubDate>Mon, 18 May 2020 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[HiNI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[scientifically]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10084</guid>
		<description><![CDATA[‘Corona will remain a part of our lives for a long time. But at the same time, we cannot allow this to happen that our lives will be confined only around the corona. We would wear masks, follow two yards &#8230; <a href="http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Many Successful CEOs Don’t Want to Retire &#8211; in Pharma Too?</title>
		<link>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-many-successful-ceos-dont-want-to-retire-in-pharma-too</link>
		<comments>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/#comments</comments>
		<pubDate>Mon, 12 Nov 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[70]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Aditya]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Basudeo]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Frazier]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[HDFC]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ITC]]></category>
		<category><![CDATA[Jack]]></category>
		<category><![CDATA[Kenneth]]></category>
		<category><![CDATA[L&T]]></category>
		<category><![CDATA[listed]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Miles]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naik]]></category>
		<category><![CDATA[Narain]]></category>
		<category><![CDATA[Pankaj]]></category>
		<category><![CDATA[Patel]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[publicly]]></category>
		<category><![CDATA[Puri]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RBI]]></category>
		<category><![CDATA[retire]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Welsh]]></category>
		<category><![CDATA[white]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yogeshwar]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9256</guid>
		<description><![CDATA[“On Eve of Retirement, Jack Welch Decides to Stick Around GE a Bit,” reported the Wall Street Journal (WSJ) on October 23, 2000. Nevertheless, even the legendary Jack Welsh was made no exception to GE’s mandatory retirement policy for the &#8230; <a href="http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Kickbacks And Bribes Oil Every Part of India’s Healthcare Machinery” &#8211; A National Shame?</title>
		<link>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame</link>
		<comments>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/#comments</comments>
		<pubDate>Mon, 07 Jul 2014 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Berger]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bribes]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[Desai]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[Ketan]]></category>
		<category><![CDATA[kickbacks]]></category>
		<category><![CDATA[Lucentis]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[means]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Nundy]]></category>
		<category><![CDATA[Parilamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Samiran]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5584</guid>
		<description><![CDATA[“Corruption ruins the doctor-patient relationship in India” - highlights an article published in the well-reputed British Medical Journal (BMJ) on 08 May 2014. The author David Berger wrote, “Kickbacks and bribes oil every part of the country’s healthcare machinery and &#8230; <a href="http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma: Now A ‘Chink in Its Armor’?</title>
		<link>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-now-a-chink-in-its-armour</link>
		<comments>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/#comments</comments>
		<pubDate>Mon, 17 Feb 2014 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[&]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[Armour]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Chink]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5000</guid>
		<description><![CDATA[Emerging trends bring to the fore a possible ‘Chink in the Armor’ of the ‘Big Pharma’, despite a number of recent belligerent moves. One such move I had deliberated in my earlier blog post. There I mentioned that 2014 report &#8230; <a href="http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are We Taking Safe and Effective Medicines?</title>
		<link>http://www.tapanray.in/are-we-taking-safe-and-effective-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-we-taking-safe-and-effective-medicines</link>
		<comments>http://www.tapanray.in/are-we-taking-safe-and-effective-medicines/#comments</comments>
		<pubDate>Wed, 13 Nov 2013 06:49:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[controllers]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[GuruFcure]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tardy]]></category>
		<category><![CDATA[unichem]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4258</guid>
		<description><![CDATA[The above headline is in no way intended to mean that this discussion is on spurious or counterfeit drugs. Today’s deliberation is on the licensed drugs, which are manufactured in India, for the patients of the country, by the manufacturers &#8230; <a href="http://www.tapanray.in/are-we-taking-safe-and-effective-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-we-taking-safe-and-effective-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>After Mollycoddling China Cracks Down on Pharma MNCs&#8230;But Why Now?</title>
		<link>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now</link>
		<comments>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/#comments</comments>
		<pubDate>Mon, 22 Jul 2013 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[aeon]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Anathema]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Chen]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[clampdown]]></category>
		<category><![CDATA[contaminated]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[crackdown]]></category>
		<category><![CDATA[Danone]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Dragon]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[enforced]]></category>
		<category><![CDATA[exemplary]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grip]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[hazards]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[land]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[meat]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[mollycoddling]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[powder]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[principle]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rat]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[staggering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[violations]]></category>
		<category><![CDATA[Zu]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2948</guid>
		<description><![CDATA[In tandem with exemplary growth in the healthcare sector, China has started confronting with some consequential hazards in form of serious regulatory violations involving, besides many others, hospitals, pharmaceutical pricing and food and drug safety, which reportedly include contaminated milk powder and &#8230; <a href="http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line</title>
		<link>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line</link>
		<comments>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/#comments</comments>
		<pubDate>Mon, 10 Jun 2013 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[blockbusters]]></category>
		<category><![CDATA[blocking]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[disparaging]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[entering]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Holland]]></category>
		<category><![CDATA[Impax]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NUT]]></category>
		<category><![CDATA[Opana]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[OxyContin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Purdue]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[TevaSante]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[ZydusCadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2234</guid>
		<description><![CDATA[To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the &#8230; <a href="http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Fraud or Negligence in Drug Quality Standards Not a Fraud on Patients?</title>
		<link>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients</link>
		<comments>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/#comments</comments>
		<pubDate>Mon, 03 Jun 2013 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boehringer]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[breach]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[charitable]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Claris]]></category>
		<category><![CDATA[contamination]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dewas]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[everywhere]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Ingelheim]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Jaslok]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical Association]]></category>
		<category><![CDATA[Mumbai]]></category>
		<category><![CDATA[OSCS]]></category>
		<category><![CDATA[paonta]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sahib]]></category>
		<category><![CDATA[Schering-Plough]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Show]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tolerance]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[trusts]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Wyeth]]></category>
		<category><![CDATA[zero]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2607</guid>
		<description><![CDATA[As we know, a substance is called a drug when it has scientifically proven and well documented efficacy and safety profile to reduce both mortality and morbidity of patients. Any fraud or negligence in the drug quality standards, for whatever &#8230; <a href="http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
